Farallon Capital Management LLC Decreases Stock Position in IQVIA Holdings Inc. $IQV

Farallon Capital Management LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 75.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 938,551 shares of the medical research company’s stock after selling 2,912,800 shares during the quarter. Farallon Capital Management LLC owned 0.55% of IQVIA worth $178,268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of IQV. Physician Wealth Advisors Inc. boosted its stake in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. increased its stake in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Atlantic Union Bankshares Corp bought a new stake in IQVIA during the 3rd quarter valued at $36,000. Asset Dedication LLC boosted its position in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after buying an additional 168 shares during the period. Finally, Rothschild Investment LLC grew its holdings in IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. UBS Group decreased their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. BMO Capital Markets set a $250.00 price objective on IQVIA in a report on Friday, February 6th. Finally, Jefferies Financial Group cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Buy” and a consensus price target of $229.13.

IQVIA Price Performance

Shares of NYSE IQV opened at $164.78 on Monday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a market capitalization of $27.96 billion, a P/E ratio of 20.96, a P/E/G ratio of 1.59 and a beta of 1.40. The company’s 50-day moving average is $201.58 and its 200 day moving average is $206.93. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.